Epigenetic regulation is central to multiple myeloma (MM) pathogenesis. Among the most critical regulators are the histone acetyltransferases CREB‑binding protein (CBP) and p300, which act as transcriptional co‑activators that maintain MYC‑driven proliferation, IRF4‑dependent survival, and plasma cell identity 1 . Pharmacologic inhibition of CBP/p300 bromodomains with CCS1477/inobrodib has shown early clinical activity in a phase 2 trials (NCT04068597) for MM, confirming these co‑activators as actionable targets 2 . However, inhibitors act via occupancy‑driven pharmacology, suppressing only catalytic function while leaving intact the non‑enzymatic scaffolding roles that are critical for oncogenic transcription 3 . As a result, their efficacy is incomplete.
Corradini et al. (Tue,) studied this question.